Mucous membrane pemphigoid: Clinical manifestations and treatment with corticosteroids, dapsone and cyclophosphamide in 5 patients;Penfigoide de mucosas: Manifestaciones clínicas y tratamiento con corticoides, dapsona y ciclofosfamida en cinco pacientes

Actas Dermo-Sifiliograficas

Volumn 96, Issue 6, 2005, Pages 357-364

  España, Agustin ^a   Del Olmo, Julio ^a   Marquina, Miren ^a   Fernández, Secundino ^a   Panizo, Carlos ^a   Maldonado, Miguel ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Cicatricial pemphigoid; Mucous membrane pemphigoid; Subepidermal bullous diseases

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAPSONE;

ADULT; AGED; ANUS; ARTICLE; BULLOUS SKIN DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; GENITAL SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LARYNX MUCOSA; MALE; MOUTH MUCOSA; PHARYNX; SKIN; SKIN MANIFESTATION;

EID: 24044540726     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-7310(05)73091-x     Document Type: Article

References (57)

1. Ahmed AR, Kurgis BS, Rogers III RS. Cicatricial pemphogoid. J Am Acad Dermatol. 1991;24:987-1001.
2. Fleming TE, Korman NJ. Cicatricial pemphigoid. J Am Acad Dermatol. 2000;43:571-91.
3. Chan LS, Yancey KB, Hammerberg C, et al. Immune-mediated subepithelial blistering diseases of mucous membranes: pure ocular cicatricial pemphigoid is a unique clinical and immunopathological entity distinct from bullous pemphigoid and other subsets identified by antigenic specifities of autoantibodies. Arch Dermatol. 1993; 129:448-55.
4. Bohn J, Benfeldt E, Dabelsteen E, Menné T. Treatment of ocular cicatricial pemphigoid with intravenous gammaglobulin. Acta Derm Venereol (Stockh). 1998;78:316-7.
5. Pandya AG. Cicatricial pemphigoid successfully treated with pulsed intravenous cyclophosphamide. Arch Dermatol. 1997;132:245-7.
6. Tauber J, De la Maza MS, Foster CS. Systemic chemotherapy for ocular cicatricial pemphigoid. Cornea. 1991;10: 185-95.
7. Bohn J, Jonsson S, Hoist R. Successful treatment of recalcitrant cicatricial pemphigoid with a combination of plasma exchange and cycophosphamide. Br J Dermatol. 1999; 141:536-40.
8. Espana A, Del Olmo J, Marquina M, Sitaru C. Penfigoide de membranas mucosas: Anticuerpos IgG e IgA frente al antigeno BP180. Actas Dermosifiliogr. En prensa 2005.
9. Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol. 1986;84:527-663.
10. Schmidt E, Skrobek C, Kromminga A, et al. Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180. Br J Dermatol. 2001;145:778-83.
11. Setterfield J, Shirlaw PJ, Kerr-Muir M, et al. Mucous membane pemphigoid: a dual circulating antibody response with IgG and IgA signifies a more severe and persistent disease. Br J Dermatol. 1998;138:602-10.
12. Setterfield J, Shirlaw PJ, Bhogal BS, Tilling K, Challacombe SJ, Black MM. Cicatricial pemphigoid: serial titres of circulating IgG and IgA antibasement membrane antibodies correlate with disease activity. Br J Dermatol. 1999; 140:645-50.
13. Christophoridis S, Büdinger L, Borradori L, Hunziker T, Merk HF, Hertl M. IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and Cicatricial pemphigoid and linear IgA bullous dermatosis. Br J Dermatol. 2000;143:349-55.
14. Leverkus M, Bhol K, Hirako Y, et al. Cicatricial pemphigoid with circulating autoantibodies to β4 integrin, bullous pemphigoid 180 and bullous pemphigoid 230. Br J Dermatol. 2001;145:998-1004.
15. Setterfield J, Theron J, Vaughan RW, et al. Mucous membrane pemphigoid: HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production. Br J Dermatol 2001; 145:406-14.
16. Zillikens D, Giudice GJ. BP180/type XVII collagen: its role in acquired and inherited disorders or the dermal-epidermal junction. Arch Dermatol Res. 1999;291:187-94.
17. Schumann H, Baetge J, Tasanen K, et al. The shed ectodomain of collagen XVII/BP180 is targeted by autoantibodies in different blistering skin diseases. Am J Pathol 2000;156:685-95.
18. Bernard P, Prost C, Lecerf V, et al. Studies of Cicatricial pemphigoid autoantibodies using direct immunoelectron microscopy and immunoblot analysis. J Invest Dermatol. 1990;94:630-5.
19. Balding SD, Prost C, Díaz LA, et al. Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. J Invest Dermatol. 1996;106:141-6.
20. Domloge-Hultsch N, Gammon WR, Briggaman RA, Gil SG, Carter WG, Yancey KB. Epilligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inhereted subepidermal blistering skin disease. J Clin Invest. 1992;90:1628-33.
21. Kirtschig G, Marinkovich M, Burgeson RE, Yancey KB. Anti-basement membrane antibodies in patients with anti-epilligrin cicatricial pemphigoid bind the α subunit of laminin 5. J Invest Dermatol. 1995;105:543-8.
22. Chan LS, Majumdar AA, Tran HH, et al. Laminin-6 and laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid. J Ivest Dermatol. 1997;108: 848-53.
23. Egan CA, Lazarova Z, Darling TN, Yee C, Cote T, Yancey KB. Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet. 2001;357:1850-1.
24. Tyagi S, Bhol K, Natarajan K, Livir-Rallatos C, Foster CS, Ahmed AR. Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization. Proc Natl Acad Sci USA. 1996;93:14714-9.
25. Bhol KC, Dans MJ, Simmons RK, Foster CS, Giancotti FG, Ahmed AR. The autoantibodies to α6β4 integrin of patients affected by ocular cicatricial pemphigoid reconize predominantly epitopes within the large cytoplasmic domain of human β4. J Immunol. 2000;165:2824-9.
26. Chan RY, Bhol K, Tesavibul N, et al. The role of antibody to human b4 integrin in conjunctival basement for ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci. 1999; 40:2283-90.
27. Bhol KC, Goss L, Kumari S, Colon JE, Ahmed AR. Auto-antibodies to human alpha6 integrin in patients with oral pemphigoid. J Dent Res. 2001;80:1711-5.
28. Hoang-Xuan T, Robin H, Demers PE, et al. Pure cicatricial pemphigoid. A distinct immunopathologic subset of cicatricial pemphigoid. Ophthalmology. 1999;106:355-61.
29. Kawahara Y, Amagai M, Ohata Y, et al. A case of cicatricial pemphigoid with simultaneous IgG autoantibodies against the 180 kD bullous pemphigoid antigen and laminin 5. J Am Acad Dermatol. 1998;38:624-7.
30. Chan LS, Vanderlugt CJ, Hashimoto T, et al. Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol. 1998;110:103-9.
31. Ahmed AR, Hombal SM. Cicatricial pemphigoid. Int J Dermatol. 1986;25:90-6.
32. Laskaris G, Sklavounou A, Stratigos J. Bullous pemphigoid, cicatricial pemphigoid, and pemphigus vulgaris: a comparative clinical survey of 278 cases. Oral Surg Oral Med Oral Pathol. 1982;54:656-62.
33. Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid. Definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138:370-9.
34. Mutasim DF. Management of autoimmune bullous diseases: Pharmacology and therapeutics. J Am Acad Dermatol. 2004;51:859-77.
35. Ahmed AR, Rogers RS III. Therapy and management of bullous pemphigoid. Clin Dermatol. 1987;5:146-54.
36. Lozada-Nur F, Huang MZ, Zhou G. Open preliminary clinical trial of clobetasol propionate oinment in adhesive paste for treatment of chronic oral vesiculo-erosive diseases. Oral Surg Oral Med Oral Pathol. 1991;71:283-7.
37. Lozada-Nur F, Miranda C, Maliksi R. Double-blinded clinical trial of 0.05 % clobetasol propionate ointment in orabase and 0.05 % flucinonide ointment in orabase in the treatment of patients with oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol. 1994;77:598-604.
38. Poskitt K, Wojnarowska F. Treatment of cicatricial pemphigoid with tetracycline and nicotinamide. Clin Exp Dermatol. 1995;20:258-9.
39. Reiche L, Wojnarowska F, Mallon E. Combination therapy with nicotinamide and tetracycline for cicatricial pemphigoid: further support for its efficacy. Clin Exp Dermatol. 1998;23:254-7.
40. Azana JM, De Misa RF, Boixeda JP, Ledo A. Topical cyclosporine for cicatricial pemphigoid. J Am Acad Dermatol. 1993;28:134-5.
41. Rogers RS III, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol. 1982;6:215-23.
42. Lozada F. Prednisone and azathioprine in the treatment of patients with vesiculoerosive oral diseases. Oral Surg Oral Med Oral Pathol. 1981;52:257-60.
43. Musette P, Pascal F, Hoang-Xuan T, et al. Treatment of cicatricial pemphigoid with pulse intravenous cyclophosphamide. Arch Dermatol. 2001;137:101-2.
44. Pandya AG, Warren KJ, Bergstresser PR. Cicatricial pemphigoid successfully treated with pulse intraveous cyclophosphamide. Arch Dermatol. 1997;133:245-7.
45. Elder MJ, Lightman S, Dart JK Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid. Br J Ophthalmol. 1995;79:264-6.
46. Appelhans M, Bonsmann G, Orge C, Brocker EB. Dexamethasone- cyclophosphamide pulse therapy in bolus autoimmune dermatoses. Hautarzt. 1993;44:143-7.
47. Bohn J, Jonsson S, Hoist R. Successful treatment of recalcitrant cicatricial pemphigoid with a combination of plasma exchange and cyclophosphamide. Br J Dermatol. 1999;141:536-40.
48. Megahed M, Schmiedeberg S, Becker J, Ruzicka T. Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol. 2001;45:256-9.
49. Sacher C, Rubbert A, Konig C, Scharffetter-Kochanek K, Krieg T, Hunzelmann N. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol. 2002;46: 113-5.
50. Ahmed AR, Colon JE. Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid. J Am Acad Dermatol. 2001;137:1181-9.
51. Urcelay ML, McQueen A, Douglas WS. Cicatricial pemphigoid treated with intravenous immunoglobulin. Br J Dermatol. 1997;137:467-84.
52. Bohn J, Benfeldt E, Dabelsteen E, Menne T. Treatment of ocular cicatricial pemphigoid with intravenous gammablobulin. Acta Derm Venereol (Stockh). 1998;78: 316-7.
53. Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmol. 1999;106:2136-43.
54. Poskitt L, Wojnarowska F. Minimizing cicatricial pemphigoid orodynia with minocycline. Br J Dermatol. 1995; 132:784-9.
55. Rogers RS. Dapsone and sulfaphyridine therapy of pemphigoid diseases. Australas J Dermatol. 1986;27:58-63.
56. Elder MJ, Leonard J, Dart JKG. Sulphapyridine: a new agent for the treatment of ocular cicatricial pemphigoid. Br J Opthalmol. 1996;80:549-52.
57. Donnenfeld ED, Perry HD, Wallerstein A, et al. Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid. Ophthalmology. 1999;106:72-9.